Concise review: current trends on applications of stem cells in diabetic nephropathy

Li, Dongwei; Wen, Zheng; Pan, Shaokang; Liu, Zhangsuo

doi:10.1038/s41419-020-03206-1

Cited by 15 publications

(5 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stem cells can be classified according to their differentiation capability: (1) pluripotent stem cells; (2) multipotent stem cells; (3) unipotent stem cells ( 230 ). Mesenchymal stem cells (MSCs) are one of the most widely studied pluripotent stem cells in DN ( 231 ). Among these stem cells, MSCs have several advantages to apply in DN therapy, such as easy harvesting, multi-lineage differentiation potential, strong immunosuppression, and no immune rejection ( 232 ).…”

Section: Clinical and Pre-clinical Therapies Targeting The Immune Sys...mentioning

confidence: 99%

Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target

Liu

2022

Front. Immunol.

View full text Add to dashboard Cite

Diabetic nephropathy (DN) is a chronic, inflammatory disease affecting millions of diabetic patients worldwide. DN is associated with proteinuria and progressive slowing of glomerular filtration, which often leads to end-stage kidney diseases. Due to the complexity of this metabolic disorder and lack of clarity about its pathogenesis, it is often more difficult to diagnose and treat than other kidney diseases. Recent studies have highlighted that the immune system can inadvertently contribute to DN pathogenesis. Cells involved in innate and adaptive immune responses can target the kidney due to increased expression of immune-related localization factors. Immune cells then activate a pro-inflammatory response involving the release of autocrine and paracrine factors, which further amplify inflammation and damage the kidney. Consequently, strategies to treat DN by targeting the immune responses are currently under study. In light of the steady rise in DN incidence, this timely review summarizes the latest findings about the role of the immune system in the pathogenesis of DN and discusses promising preclinical and clinical therapies.

show abstract

Section: Clinical and Pre-clinical Therapies Targeting The Immune Sys...mentioning

confidence: 99%

Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target

Liu

2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…In addition, DN manifests itself as glomerular damage, glomerular hypertrophy, and thickening of the glomerular basement membrane. Patients who have DN typically have a poor renal prognosis since their condition is often misdiagnosed and difficult to treat ( 38 , 39 ). This may be one factor that contributes to the poor renal prognosis.…”

Section: Discussionmentioning

confidence: 99%

Machine-learning algorithm-based prediction of a diagnostic model based on oxidative stress-related genes involved in immune infiltration in diabetic nephropathy patients

et al. 2023

View full text Add to dashboard Cite

Diabetic nephropathy (DN) is the most prevalent microvascular consequence of diabetes and has recently risen to the position of the world’s second biggest cause of end-stage renal diseases. Growing studies suggest that oxidative stress (OS) responses are connected to the advancement of DN. This study aimed to developed a novel diagnostic model based on OS-related genes. The differentially expressed oxidative stress-related genes (DE-OSRGs) experiments required two human gene expression datasets, which were given by the GEO database (GSE30528 and GSE96804, respectively). The potential diagnostic genes were identified using the SVM-RFE assays and the LASSO regression model. CIBERSORT was used to determine the compositional patterns of the 22 different kinds of immune cell fraction seen in DN. These estimates were based on the combined cohorts. DN serum samples and normal samples were both subjected to RT-PCR in order to investigate the degree to which certain genes were expressed. In this study, we were able to locate 774 DE-OSRGs in DN. The three marker genes (DUSP1, PRDX6 and S100A8) were discovered via machine learning on two different machines. The high diagnostic value was validated by ROC tests, which focused on distinguishing DN samples from normal samples. The results of the CIBERSORT study suggested that DUSP1, PRDX6, and S100A8 may be associated to the alterations that occur in the immunological microenvironment of DN patients. Besides, the results of RT-PCR indicated that the expression of DUSP1, PRDX6, and S100A8 was much lower in DN serum samples compared normal serum samples. The diagnostic value of the proposed model was likewise verified in our cohort, with an area under the curve of 9.946. Overall, DUSP1, PRDX6, and S100A8 were identified to be the three diagnostic characteristic genes of DN. It’s possible that combining these genes will be effective in diagnosing DN and determining the extent of immune cell infiltration.

show abstract

“…In addition, Corti et al unveiled the neuroprotective effect of bone marrow-derived c-kit + cells on degenerating motor neurons through anti-in ammatory function in a mouse model of amyotrophic lateral sclerosis [52]. It has been suggested that the trophic effect could be a major mechanism for the therapeutic properties of stem cell transplantation [53,54] by which stem cells promote cytoprotective, anti-in ammatory, and immune regulatory effects in a paracrine, endocrine, or autocrine manner and thus involved in improving diabetic nephropathy [55].…”

Section: Discussionmentioning

confidence: 99%

Bone marrow-derived c-kit positive stem cell administration protects against diabetes-induced nephropathy in a rat model by reversing PI3K/AKT/GSK-3β pathway and inhibiting cell apoptosis

et al. 2023

View full text Add to dashboard Cite

Stem cell-based therapy has been proposed as a novel therapeutic strategy for diabetic nephropathy. This study was designed to evaluate the effect of systemic administration of rat bone marrow-derived c-kit positive (c-kit ) cells on diabetic nephropathy in male rats, focusing on PI3K/AKT/GSK-3β pathway and apoptosis as a possible therapeutic mechanism. Twenty-eight animals were randomly classi ed into four groups: Control group (C), diabetic group (D), diabetic group, intravenously received 50 μl phosphatebuffered saline (PBS) containing 3×10 5 c-kitcells (D+ckit -); and diabetic group, intravenously received 50 μl PBS containing 3×10 5 c-Kit positive cells (D+ckit + ). Control and diabetic groups intravenously received 50 μl PBS. C-kit + cell therapy could reduce renal brosis, which was associated with attenuation of in ammation as indicated by decreased TNF-α and IL-6 levels in the kidney tissue. In addition, c-kit + cells restored the expression levels of PI3K, pAKT, and GSK-3β proteins. Furthermore, renal apoptosis was decreased following c-kit + cell therapy, evidenced by the lower apoptotic index in parallel with the increased Bcl-2 and decreased Bax and Caspase-3 levels. Our results showed that in contrast to c-kitcells, the administration of c-kit + cells ameliorate diabetic nephropathy and suggested that c-kit + cells could be an alternative cell source for attenuating diabetic nephropathy.

show abstract

Concise review: current trends on applications of stem cells in diabetic nephropathy

Cited by 15 publications

References 121 publications

Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target

Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target

Machine-learning algorithm-based prediction of a diagnostic model based on oxidative stress-related genes involved in immune infiltration in diabetic nephropathy patients

Bone marrow-derived c-kit positive stem cell administration protects against diabetes-induced nephropathy in a rat model by reversing PI3K/AKT/GSK-3β pathway and inhibiting cell apoptosis

Contact Info

Product

Resources

About